The ZYNLONTA therapy. ADCT targets US lymphoma patients with a focused antibody-drug treatment

ZYNLONTA from ADC Therapeutics gained FDA accelerated approval in 2021 for relapsed or refractory DLBCL after two prior lines of therapy. Anyone holding ADC Therapeutics stock (NYSE: ADCT, ISIN CH0498599052) should know this product.

By Julian Reed, ad hoc news New Launch Desk. Reviewed July 07, 2026, 7:14 PM ET. Details in the imprint.

ZYNLONTA is the kind of drug name you see on a small pharmacy shelf label, tucked between familiar cancer medicines, yet the vial inside represents a very specific bet on antibody-drug conjugates in aggressive lymphoma. Under the fluorescent lights, the solution looks clear and clinical, but oncology nurses know they are hanging a targeted cytotoxic payload. One hematologist at a New Jersey community center likened the infusion day calm to "a quiet chess match against the disease".

What ZYNLONTA is approved for

ZYNLONTA (loncastuximab tesirine-lpyl) is an antibody-drug conjugate indicated in the US for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, after at least two prior systemic therapies. The drug targets CD19, a surface antigen broadly expressed on B-cell malignancies. ADCT won FDA accelerated approval in April 2021 based on overall response rates in the phase 2 LOTIS-2 trial.

DLBCL is the most common type of non-Hodgkin lymphoma, and the approved label makes ZYNLONTA a third-line or later option for patients who have already been through standard regimens such as R-CHOP and potentially CAR-T therapy. Under the US prescribing information, ZYNLONTA is administered as an intravenous infusion every three weeks, with dose adjustments guided by toxicity, including edema, effusions, and cytopenias.

How the therapy is given in practice

In a typical US infusion room, ZYNLONTA comes out of the fridge, is reconstituted and diluted into an IV bag, and then hung on a pole for a controlled infusion over about 30 minutes, according to the prescribing information and nurse training materials. The colorless liquid belies the fact that the ADC payload, SG3199, is a highly potent pyrrolobenzodiazepine (PBD) dimer designed to crosslink DNA. Nurses closely watch for infusion-related reactions and skin changes, while lab techs track platelets and neutrophils.

ADCT emphasizes premedication and monitoring in its professional materials, including guidance to manage serious infections, hepatic toxicity and fluid retention. One oncology pharmacist interviewed at a New York hospital described the first day they stocked ZYNLONTA as "bringing in a scalpel, not a hammer" because of the focused mechanism. The drug is dispensed under restricted distribution via specialty wholesalers, with reimbursement discussions often involving Medicare Part B and commercial payers.

US availability and pricing

ZYNLONTA is commercially available in the US by prescription only and is typically supplied in 10 mg single-dose vials, according to the official product information. It is not a consumer-facing product; access runs through oncology practices and hospitals that meet handling standards for cytotoxic drugs. ADCT has noted coverage agreements with major US insurers and Medicare, indicating that reimbursement is possible but may require prior authorization.

List pricing is not displayed on the consumer-facing portion of ADCT’s site, but specialty pharmacy data and payer documents cited in trade coverage suggest that per-cycle costs run into the tens of thousands of dollars for a full dose, in line with other third-line lymphoma biologics. For patients, the practical question often becomes whether they qualify for assistance programs. ADCT references copay support for eligible US patients through its ZYNLONTA support services.

Clinical data behind ZYNLONTA

The LOTIS-2 trial, published in peer-reviewed form and summarized by ADCT, enrolled 145 adult patients with relapsed or refractory DLBCL who had received a median of three prior therapies. According to the data, the overall response rate to ZYNLONTA was about 48%, with a complete response rate near 24%. Median duration of response was around 10 months among responders. These numbers underpin the FDA’s accelerated approval, which depends on confirmatory studies.

Common adverse reactions in LOTIS-2 included fatigue, neutropenia, thrombocytopenia, anemia, and skin reactions, consistent with the drug’s mechanism of targeted DNA crosslinking. Serious events such as infections and effusions require careful management. In interviews, ADCT CEO Ameet Mallik has argued that the efficacy and manageable safety profile make ZYNLONTA a meaningful option for patients who have exhausted standard-of-care therapies. US hematologists tend to compare the data to other CD19-targeting approaches, including CAR-T, but note that ZYNLONTA does not require complex cell processing.

Competitive landscape in aggressive lymphoma

For US investors reading the label details, ZYNLONTA sits in a crowded and evolving space. Other therapies in the relapsed/refractory DLBCL setting include CAR-T products like axicabtagene ciloleucel and tisagenlecleucel, and monoclonal antibodies such as polatuzumab vedotin. What differentiates ZYNLONTA is the specific CD19 antibody-drug conjugate construct and its positioning for patients who may not be candidates for CAR-T due to comorbidities or logistics.

Carve-outs in NCCN guidelines and payer policies will determine real-world uptake. Analysts tracking ADCT have pointed out in recent notes that ZYNLONTA’s sales trajectory depends on how aggressively the company can educate community oncologists beyond academic centers. One Boston-based sell-side analyst described the brand as "recognizable to specialists, still emerging in community practice" in a March 2026 note, echoing prescription data that show concentrated use among high-volume lymphoma centers.

Manufacturing and supply reliability

Antibody-drug conjugates are manufacturing-intensive, and any disruption can ripple across clinics. ADCT contracts manufacturing to specialized facilities, and the company has reported periodic supply updates through its investor relations channels. As of its latest corporate presentation, ADCT said it maintained adequate inventory of ZYNLONTA to serve US and European markets, following earlier industry-wide challenges in biologics supply chains.

From a practical standpoint, US pharmacists care less about where the plant is located and more about whether the NDC is orderable in their wholesaler systems. In recent months, major distributors’ online catalogs have listed ZYNLONTA vials as available without backorder flags. That said, ADCs usually require cold-chain logistics and careful handling, so smaller practices often rely on just-in-time ordering rather than storing many vials on site. Supply stability feeds into physician confidence when choosing among later-line options.

Regulatory status and future studies

The FDA granted ZYNLONTA accelerated approval, which means continued authorization is contingent on confirmatory evidence of clinical benefit. ADCT has multiple LOTIS trials running or planned, including combinations with other agents in earlier treatment lines, according to its pipeline overview. European regulators have also evaluated loncastuximab tesirine, with a conditional marketing authorization granted in the EU in 2021 for a similar indication.

Future data in first or second-line settings could expand ZYNLONTA’s commercial footprint, though that path is scientifically and competitively challenging. ADCT’s R&D team, led by Chief Scientific Officer Dr. Patrick Amstutz in its earlier years, has described a broader strategy to use its ADC platform against multiple hematologic malignancies. For US physicians, however, the near-term reality is that ZYNLONTA remains a third-line or later option requiring careful patient selection and toxicity monitoring.

What it means for ADC Therapeutics stock

For US retail investors, the key is that ZYNLONTA is currently ADCT’s primary commercial product and revenue driver, according to recent earnings presentations. Its performance in the US market, including new center adoption and duration of therapy, feeds directly into cash flow and into the company’s ability to fund its broader ADC pipeline. Shares of ADC Therapeutics (NYSE: ADCT) trade in US dollars, and ZYNLONTA’s sales trends are frequently highlighted in quarterly results, but no single product eliminates the inherent risks of biotech investing.

Key facts on ZYNLONTA

• Product: ZYNLONTA (loncastuximab tesirine-lpyl)
• Manufacturer: ADC Therapeutics SA
• Category: New launch oncology therapy
• Launch: FDA accelerated approval in the US in April 2021 for relapsed or refractory DLBCL
• MSRP / Price: Specialty oncology pricing; per-cycle costs typically in the tens of thousands of US dollars for a full dose under US reimbursement schedules
• Availability: Prescription-only through US oncology centers and hospitals, with coverage via Medicare and commercial insurers subject to prior authorization
• Target audience: Adult patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies, and US investors tracking ADC Therapeutics
• Standout / USP: CD19-directed antibody-drug conjugate delivering a potent PBD dimer payload, positioned for third-line or later DLBCL in patients who may not be eligible for CAR-T therapy

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.